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Purpose: To assess the effect of intravitreal and posterior subtenon injections of triamcinolone acetonide 
(TA) on intraocular pressure (IOP).
Methods: we reviewed 42 consecutive eyes after intravitreal TA injection (IVTA) and 43 eyes following 
posterior subtenon TA injection (PSTA). All cases had a minimum follow-up time of three months. After 
injection, the value and time of the maximal IOP, the amount of IOP elevation and the needs of the 
medication were assessed. 
Results: The IOP increased significantly (p<0.001) from 16.3±2.5 mmHg preoperatively to a mean 
maximum of 21.7±5.3 mmHg in the IVTA group, and from 15.3±4.5 mmHg to 20.6±3.0 mmHg in the 
PSTA group. An elevation in the IOP of more than 5 mmHg from the baseline IOP was seen in 52.4% of 
the IVTA group at a mean time of 3.1 weeks postoperatively, and 44.2% of the PSTA group displayed an 
IOP elevation at 5.9 weeks. 
Conclusions: Both developed significant elevations of IOP, but this appeared at a later date in the PSTA 
group. Careful follow-up after local injection of steroids is necessary.  Korean Journal of Ophthalmology 
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Posterior subtenon injections of intermediate or long-acting 
corticosteroids are widely used as the initial treatment for 
visual loss caused by retinal edema or other reversible effects 
of inflammation in patients with intermediate uveitis.
1 A 
subtenon injection delivers a large amount of the drug to the 
posterior segment of the eye via transscleral absorption, and 
it also minimizes the risk of systemic side effects.
2,3
Recently, intravitreal injections of triamcinolone acetonide 
(IVTA) have been widely used as an effective method in the 
treatment of conditions such as uveitis and macular edema 
that are secondary to retinal vascular disease. IVTA has also 
been used to treat intraocular proliferations such as prolifera-
tive vitreoretinopathy and choroidal neovascularization 
resulting from age-related macular degeneration.
4-7
In comparison with other corticosteroids, triamcinolone 
acetonide (TA) is a minimally water-soluble steroid in a 
suspension form; as a result, it can maintain a long-term 
intraocular concentration for an expanded period of time. TA 
has been reported to be present in the eye for as long as six 
months after the injection, and recent studies have found it 
to be present in measurable concentrations up to 1.5 years 
after IVTA 20-25 mg.
8 
Because both topical and systemic corticosteroids are 
known to be associated with an increase in intraocular 
pressure (IOP),
9 this extended intraocular presence of TA 
may lead not only to secondary ocular hypertension but also 
to steroid-induced secondary open-angle glaucoma necessi-
tating trabeculectomy.
10 
The purpose of this study was to assess the effects of TA 
when delivered into the vitreous or posterior subtenon space 
on the IOP.
Materials and Methods
A retrospective chart review was performed to identify 
patients who had received intravitreal or posterior subtenon 
injections of TA for the treatment of chronic macular edema, 
choroidal neovascularization, or uveitis. Patients also had to 
have had at least three months of follow-up from January 
2000 to December 2003. They were excluded if they had had 
a previous intraocular surgery, acute inflammation in the 
anterior chamber, an IOP value higher than 22 mmHg, or a Korean  J  Ophthalmol  Vol.20,  No.2,  2006
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Groups Preinjection  IOP 
(mmHg)
Maximum  IOP  after  injection
(mmHg) p  value Time  of  Maximum  IOP 
(week)
IVTA
PSTA
16.3±2.5
15.3±4.5
21.7±5.3
20.6±3.0
p<0.001
p<0.001
10.2±11.5
12.6±15.1
IVTA:  Introvitreal  injection  of  triamcinolon  acetonide,  PSTA:  Posterior  subtenon  injection  of  triamcinolon  acetonide
Table 1. Intraocular  pressure  after  the  injection  of  triamcinolone  acetonide  (Mean±SD)
Groups
No.  of  eyes  with  Elevated  IOP  (%) Time  of  elevated  IOP  (week)
5  mmHg 10  mmHg 5  mmHg  10  mmHg 
IVTA
PSTA
p  value
42  (52.4)
19  (44.2)
0.71
4  (9.5)
7  (16.3)
0.46
3.1±2.1
5.9±9.0
3.8±3.6
7.6±13.7
IVTA:  Introvitreal  injection  of  triamcinolon  acetonide,  PSTA:  Posterior  subtenon  injection  of  triamcinolon  acetonide
Table 2. Elevated  intraocular  pressure  after  the  injection  of  triamcinolone  acetonide  (Mean±SD)
history of glaucoma. A total of 85 eyes in 66 patients met 
the inclusion criteria and were eligible for the study. 
One group, made up of patients in which TA had been 
injected intravitreally (the IVTA group), included 42 
consecutive eyes of 41 patients. Twenty-one eyes in 20 men 
and 21 eyes in 21 women were included. The mean age of 
the patients was 58.5 years (range, 39-75 years). Indications 
were diabetic macular edema (24 eyes), retinal vascular 
occlusive disease (eight eyes), uveitis (five eyes), and 
exudative AMD (five eyes). 
In the other group, TA was injected into the posterior 
subtenon space (PSTA group). This group consisted of 43 
consecutive eyes in 25 patients. Twenty-eight eyes in 16 men 
and 15 eyes in 9 women were included. The mean age was 
48.3 years (range, 33-80 years). Most patients were 
diagnosed with idiopathic intermediate uveitis, with the 
exception that two eyes had Behcet and Harada Disease.
The intravitreal injections of TA were carried out in an 
office setting. Drops of proparacaine hydrochloride 0.5% 
(Alcaine, Alcon. Inc.) and ofloxacin 0.3% were administered 
to the affected eyes. Then the eyelids and surrounding areas 
were scrubbed with Povidone-iodine 5% and an eyelid specu-
lum was placed. TA (40 mg/ml, Dong-Kwang Pharmaceutical 
Company) 4 mg in 0.1 ml was injected into the vitreous 
cavity through the inferotemporal pars plana, 3.5 mm 
posterior from the limbus in the phakic eyes. 
After injection, patients were asked to maintain a sitting 
position. The anterior and posterior segments and the IOP 
were checked two hours after the injection.
For the posterior subtenon injection, TA 40 mg (1 ml) was 
administered into the inferotemporal or inferonasal posterior 
fornix through a 5/8-inch, 26-gauge needle attached to a 
tuberculin syringe. All patients were prescribed ofloxacin 
0.3% eye drops four times daily for seven days.
The applanation tonometry measurements, slit lamp exami-
nation and fundus examination for both the injected and 
fellow eyes were recorded on the day of injection and one 
day, one week, two weeks, and one month after the injection, 
and thereafter as dictated by the clinical response. The data 
were analyzed using a two-sample t-test for independent 
samples that are not distributed normally. 
The pre-injection IOP was statistically compared with the 
post-injection IOP. The statistical analyses of the differences 
between the mean pre-injection pressure and post-injection 
pressure during the follow-up periods were performed with 
a two-tailed paired t-test using the statistical software 
program SPSS version 11.5. The effects of diabetes, hyper-
tension, age and refractive errors on IOP and the change of 
IOP after injection were also analyzed with a Spearman rank 
correlation coefficient using SPSS version 11.5. 
Results
In the IVTA group, the difference between the mean 
pre-injection pressure (16.3±2.5 mmHg, n=42 eyes) and the 
maximum post-injection pressure (21.7±5.3 mmHg, n=42 
eyes) that occurred after 10.2±11.5 weeks (mean time) was 
statistically significant (p<0.001, paired two-tailed t-test) 
(Table 1).
In the PSTA group, the difference between the mean 
pre-injection pressure (15.3±4.5 mmHg, n=43 eyes) and the 
maximum post-injection pressure (20.6±3.0 mmHg, n=43 
eyes), which occurred after 12.6±15.1 weeks (mean time), 
was also statistically significant (P<0.001, paired two-tailed 
t test) (Table 1).
Twenty-three out of 42 eyes (52.4%) in the IVTA group 
had an IOP increase of 5 mmHg or greater. The mean time 
for a 5-mmHg or greater increase in IOP to occur was 3.1 
weeks [standard deviation (SD)=2.1 weeks]. Nineteen out of 
43 eyes (44.2%) in the PSTA group demonstrated an IOP 
increase of 5 mmHg or greater. The mean time for an 
increase in IOP of 5 mmHg or more to occur was 5.9 weeks 
(SD=9.0 weeks). The difference between the two groups was 
not statistically significant (p=0.71) (Table 2).SY  Jae,  et  al.  TRIAMCINOLONE-INDUCED  INTRAOCULAR  PRESSURE  ELEVATION
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Groups
Number  of  eyes  using  medications  (%) Total  number 
of  eyes  using 
medications
(%)
Duration  of 
medication
(month) 1  month 3  months 6  months 9  months 12  months
IVTA
PSTA
9  (56.3)
8  (53.3)
  8  (50.0)
10  (66.7)
9  (56.3)
7  (46.7)
5  (31.3)
3  (20.0)
1  (6.3)
0  (0)
16  (35.7)
15  (34.9)
3.2±4.3
2.9±4.1
IVTA:  Introvitreal  injection  of  triamcinolon  acetonide,  PSTA:  Posterior  subtenon  injection  of  triamcinolon  acetonide
Table 3. Required medications for elevated intraocular pressure after triamcinolone acetonide injection during the follow- 
up  period 
Number  of  eyes 
IVTA  group PSTA  group
Drug Duration  of  treatment 
(month) Drug Duration  of  treatment 
(month)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Cos
Mik
Mik
Cos+Alph
Alph
Mik
Xal
Cos
Xal
Cos+Alph+Xal
Cos
Cos+Alph
Mik
Alph
Xal
Cos
2
1
1
6
2
2
3
3
3
9
2
7
2
2
3
3
Cos
Xal
Alph
Cos
Cos+Alph
Cos+Alph+Xal
Cos+Alph+Xal
Mik
Cos
Cos
Mik
Alph
Mik
Cos+Alph
Mik
2
3
3
1
6
6
4
2
1
3
4
1
3
3
1
Average 3.19 2.87
A l p h  =  A l p h a g a n ,  C o s  =  C o s o p t ,  M i k  =  M i k e l a n ,  X a l  =  X a l a t a n .
IVTA:  Introvitreal  injection  of  triamcinolon  acetonide,  PSTA:  Posterior  subtenon  injection  of  triamcinolon  acetonide
Table 4. A  comparison  of  anti-glaucoma  medications  in  our  two  groups
Four out of 42 eyes (9.5%) had an increase in IOP of 10 
mmHg or greater at a mean of 3.8 weeks (SD=3.6) in the 
IVTA group, and 7 of 43 eyes (16.3%) at a mean of 7.6 
weeks (SD=13.7) in the PSTA group also had an IOP 
increase of 10 mmHg or greater. The difference was not 
statistically significant (P=0.46) (Table 2). Sixteen eyes 
(35.7%) from the IVTA group and 15 eyes (34.9%) in the 
PSTA group were found to have an IOP of 22 mmHg or 
higher, and they were treated with IOP-lowering eye drops. 
The mean duration of medication was 3.2 months in the 
IVTA group and 2.9 months in the PSTA group (Table 3, 
4). 
The elevated IOP was successfully controlled with IOP- 
lowering eye drops in most patients, except for one eye 
(2.4%) in the IVTA group and two eyes (4.7%) in the PSTA 
group that had undergone a trabeculectomy. Most of the 
topical anti-glaucoma medications were successfully discon-
tinued 12 months postoperatively. 
The presence of diabetes mellitus or hypertension, age and 
refractive errors (-3.5D~+3.5D) had no influence on the 
change of the IOP in either group (p>0.05) (Table 5). Other 
severe ocular complications such as vitreous hemorrhage, 
cataracts, retinal detachment, or endophthalmitis were not 
observed in either of the two groups.
Discussion
Intraocular neovascular diseases such as exudative AMD 
and proliferative diabetic retinopathy are one of the leading 
causes of acquired vision loss. In addition, edematous 
diseases of the retina such as diffuse diabetic macular edema 
and persistent cystoid macular edema also significantly 
contribute to the incidence of acquired vision loss. Steroids 
can be used for these diseases because they reduce vascular 
leakage and inhibit intraocular cell proliferations.
4-7 Both 
systemic and local administration methods of the steroids 
have been used to deliver the drug, but systemic adminis-
tration has limitations because of its various systemic side 
effects and poor penetration into the eye. The local 
administration of steroids such as subtenon or intravitreal 
injections reduces these limitations and maintains effective 
intraocular concentrations. Korean  J  Ophthalmol  Vol.20,  No.2,  2006
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IVTA PSTA
No.  of  eyes Preinjection  IOP 
(mmHg)
Maximum  IOP
(mmHg) No.  of  eyes Preinjection  IOP 
(mmHg)
Maximum  IOP
(mmHg)
DM +
-
p  value
27
15
16.8±2.5
15.5±2.3
0.08
21.8±4.3
21.6±6.9
0.92
15
28
15.6±3.1
15.2±4.3
0.21
20.7±8.3
21.2±7.2
0.73
HT +
-
p  value
16
26
16.6±2.7
16.9±1.9
0.12
21.3±5.1
21.9±5.7
0.67
12
31
16.0±4.0
15.8±4.3
0.09
21.8±7.2
21.6±8.3
0.47
Age ≤60
>60
p  value
18
24
16.7±2.3
16.6±1.3
0.94
21.4±4.1
21.8±6.8
0.72
26
17
15.6±4.6
16.0±3.3
0.64
21.4±5.1
21.8±6.8
0.52
Refractive -0.25~-3.5D
error 0~+3.5D
p  value
25
17
15.9±2.5
16.2±2.1
0.31
21.7±4.6
22.1±6.3
0.53
19
24
15.7±5.1
15.9±3.8
0.27
21.9±5.4
22.1±7.1
0.33
IVTA: Introvitreal injection of triamcinolon acetonide, PSTA: Posterior subtenon injection of triamcinolon acetonide, DM; Diabetes mellitus, 
HT;  Hypertension.
Table 5. Effects  of  DM,  HT,  age  and  refractive  errors  on  IOP  after  injection  of  triamcinolone  acetonide
The most common complication of local or systemic 
steroids is the elevation of IOP. Corticosteroid-induced ocular 
hypertension is a well-known phenomenon. It has been 
speculated that a genetic difference exists between cortico-
steroid responders and nonresponders, and that patients who 
show an increase in IOP have a different or a more sensitive 
corticosteroid receptor. The mechanism of elevated IOP due 
to steroids has been thought to be secondary to an increased 
resistance to aqueous outflow. This event may be induced by 
the accumulation of polymerized glycosaminoglycans in the 
trabecular meshwork, an increased expression of collagen, 
elastin, or fibronectin in the extracellular matrix, a decrease 
in the expression of extracellular proteinases, the suppression 
of phagocytosis by the trabecular endothelium, and a 
reorganization of the trabecular meshwork cell cytoskeleton 
into cross-linked actin networks.
11 
TA is commonly used due to its longer half-life (1.6 days) 
than that of dexamethasone (2.5 hours); its minimal water 
solubility also contributes to its longer duration of action. 
However, the longer duration of action also increases the 
incidence of ocular hypertension.
Using indirect ophthalmoscopy and scleral depression, 
Sophie et al.
13 noted the presence of TA crystals in the 
vitreous for at least 12 weeks. In contrast, Scholes et al.
13 
reported a marked change in the appearance of what was 
thought to be TA, and they were unable to quantify the 
steroid using indirect ophthalmoscopy. 
Beer et al.
14 determined that measurable concentrations of 
TA would be expected to last for approximately three months 
(93±28 days) in the non-vitrectomized eyes. Although the 
intraocular concentration of TA may fall below the thera-
peutic range in different clinical settings well before 90 days 
have passed, the persistence of even a trace amount may be 
related to the prolonged ocular hypertension occasionally 
seen in patients. It was also reported that the elevated IOP 
levels associated with IVTA that were not controlled with 
maximal anti-glaucoma medication could effectively be 
treated through a vitrectomy-assisted removal of the TA.
15
The incidence of elevated IOP in eyes receiving IVTA was 
high and ranged from 20-52%.
16-18 Sophie et al.
12 found that 
21 of 43 eyes (48.8%) demonstrated an increase in IOP of 
5 mmHg or greater, and 12 of 43 eyes (27.9%) had an IOP 
increase of 10 mmHg or greater after a 4-mg intravitreal TA 
injection. 
The ranges of our IOP increases were from 3 to 22 mmHg 
in the IVTA group and from 2 to 18 mmHg in the PSTA 
group. We classified the increase in IOP into either the 5 
mmHg or greater category or the 10 mmHg or greater 
category in our disposition. Our study showed a similar 
incidence of increase in IOP in both categories, so that 23 
of 43 eyes (52.4%) had an increase in IOP of 5 mmHg or 
greater, and 4 of 43 eyes (9.5%) had an IOP increase of 10 
mmHg or greater. Yang et al. noted that the IOP in IVTA 
is more elevated at a younger age (<60 years),
19 but our 
study showed no relationship between the elevation of IOP 
and the patient’s age (Table 5).
The subtenon route is routinely used for the administration 
of steroids to the posterior segment, but the need to diffuse 
across the sclera and the vascular bed in the choroid coupled 
with the highly variable rate of steroid dissolution from 
crystals make intraocular steroid levels variable and difficult 
to assess and to adjust. Kalina et al.
20 reported that pharma-
cologically-active triamcinolone was identified for up to 13 
months following subconjunctival injection (with a range 
from 3 to 13 months). Medically-unresponsive IOP elevation 
may occur as late as six months after a periocular triam-
cinolone injection or the surgical excision of a subconjunc-
tival deposit. 
The onset of pressure increase in the PSTA group was 
noted at a mean of 7.1 weeks (with a range of 1.5 to 16 SY  Jae,  et  al.  TRIAMCINOLONE-INDUCED  INTRAOCULAR  PRESSURE  ELEVATION
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weeks) and lasted a mean duration of three months (with a 
range of one to five months).
21 Glaucoma secondary to 
periocular repository corticosteroids tends to be of a delayed 
onset and a long duration.
21,22 However, the role of posterior 
subtenon corticosteroids in ocular hypertension is not always 
clear because the increased intraocular pressure may be a 
result of the disease itself or it could be influenced by the 
effects of corticosteroids. 
It was reported that 12% of patients with acute inflam-
mation and 27% of patients with chronic inflammation had 
elevated IOP levels.
23 However, Kim et al.
24 determined that 
the true elevation percentage of IOP due to inflammation is 
12% in acute inflammation because many factors (such as 
PAS etc.) can influence the elevation of IOP in the presence 
of chronic inflammation. Because we excluded patients who 
had acute inflammation in the anterior chamber before 
injection, true cases of elevated IOP with inflammation were 
not included. Therefore, the elevation of IOP in the PSTA 
group seems to be an effect of the TA itself.
We also found that the increases in IOP of both 5 mmHg 
and 10 mmHg or greater appeared later in the PSTA group 
than in the IVTA group, but the amount of elevated IOP and 
duration of anti-glaucoma medication needed were similar in 
both groups. One eye (2.4 %) of 42 eyes in the IVTA group 
and two eyes (4.7 %) of 43 eyes in the PSTA group received 
a trabeculectomy due to medically uncontrolled glaucoma. 
IOP-lowering eye drops were not used in patients whose 
IOP was 21 mmHg or less, even if they showed an increase 
in IOP of 5 mmHg or greater postoperatively. 
While most patients who had elevated IOP were 
well-controlled with IOP-lowering medications, some of them 
needed surgical treatment. A careful follow-up of IOP levels 
should be performed in all patients who have received 
periocular and intravitreal steroid injections. 
The small number of patients in the study group is one 
of the limitations of our study. Prospective studies of a larger 
study group are necessary to better demonstrate the effect of 
periocular and intravitreal steroid injections on IOP. 
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